Great hopes here on the results I'm afraid I can't imagine how good they would have to be to fire up the share price in these tepid markets |
"Anyone employed in financial institutions (and their spouses)has to seek permission to buy an equity like OXB from their compliance department"
A very good point steeplejack and one of a number of changes for the worst that have crept into our system unannounced. |
There’s a reasonable slug of stock on offer again today ie 25000 shares are on offer at a tad below 193p on quote and deal.
One can only hope that the analysts have been woefully amiss in monitoring OXBs recent progress and that the upcoming results will confirm substantial progress leading to a sharp rerating.Of course,you would hope that an analyst worth his salt would be able to discern progress on an ongoing basis rather than waiting for the ‘pitstop’; health check that biannual results provide.
Private clients that select individual stocks are becoming increasingly rare.Anyone employed in financial institutions (and their spouses)has to seek permission to buy an equity like OXB from their compliance department and are encouraged to purchase investments managed by third parties ie investment trusts,unit trusts and ETFs.It would be encouraging if a specialist fund decided to aggressively buy here.The lack of liquidity would then at least work in holder’s interests. |
Nice chart showing the development route of CAR-T in the US and EU HTTps://www.linkedin.com/posts/alliancerm_another-big-step-forward-for-car-t-cell-therapies-activity-7186036625582301185-H51Z?utm_source=share&utm_medium=member_android |
 Very possibly Phil (and another excellent piece of sleuth work btw).
I've mentioned it before but I'm a big fan of Seb. His cv proves that he's a top bloke, but of course what really matters for us is what he's achieved since he's been with OXB.
OXB have always attracted top people and the men and women where we know their names are on a par with anybody in this business.
But, as the lead article in the Times famously asked in different words - now the covid vaccine has finished where is the money going to come from to fill that gap?
We went from having 2 business enquires per month to 2 per week with Seb as head of that team and their win rate is astonishing.
Our last normal year (2019) before the insanity of covid and the lockdowns and we had 8 partners. Two of those were Axovant and AZ, so one bust and one simply an open but dormant contract.
At the interims last year we had 25 partners and it will be many more than that a week on Monday. Almost all of that is down to Seb and his team.
If (after seeing what was on the cards at OXB) he also brought in IM with the ABL deal (if you can't beat them, join them) then he deserves every penny we pay him - which I suspect will be a lot.
8 working days to go... |
Interestingly our CCO, Seb is/was a consultant for Mereiux Investment Partners from January 23-present.
Now, Mereiux investment partners are 60% owned by Institut Mereiux, from whom we have just bought ABL. Seems like Seb could be the real deal broker? |
Following on from the PB link the other day:-
6 years after launch UK recommends routine roll out of CAR-T therapy Kyriah – but do you know its UK development heritage?
Last week NICE recommended Kymriah personalised immunotherapy to treat blood cancer be made routinely available on the NHS for children and young adults.
Children and young adults with a form of leukaemia that develops rapidly are set to benefit after NICE recommended an innovative, life-extending treatment where the person’s own immune cells are modified to fight the cancer. The treatment has been available through the NHS’s Cancer Drugs Fund since December 2018, with this new guidance now recommending its routine rollout – a full six years later.
This breakthrough product has important UK heritage, having emerged from research at the University of Pennsylvania. It was back in 2017 that the FDA granted its first approval for the CAR-T product, following crucial evidence to the regulator from UK biotech Oxford Biomedica, the sole manufacturer of the lentiviral vector that encodes the CD19-directed chimeric antigen receptor in Kymriah. Oxford Biomedica signed an agreement with Novartis in July 2017 for the commercial and clinical supply of lentiviral vectors used to generate Kymriah. As announced in October 2014, Oxford Biomedica also receives royalties on sales of Novartis CAR-T products. One of the key breakthrough products wouldn’t be the blockbuster it is today if it wasn’t for the manufacturing know-how of a key UK biotech player. It is a shame that heritage isn’t part of the NICE press release to link up the full story.
From
Note the last paragraph there - at least someone in the industry appreciates what OXB does ;) |
I think for people with family hypercholesterolemia and so looking at their first heart attack in their 40s then this must be of great interest. Thankfully that's quite rare. For the rest of us I think cholesterol is a necessary building block for a lot of important things (and if it wasn't then why would our livers make it?).
Having said that the world is mad - like the NN mega blockbuster drug (potentially the most lucrative prescription drug ever) as an alternative to eating less. |
Currently relieved that I wagered Dom's pound and not my own.
9 trading days left before the results. |
Yes H, I think In-vivo and gene editing are the next big advances.
Our findings demonstrate that the T-Charge™ manufacturing platform successfully maintains highly heterogeneous transduced Tscm clones with self-renewal potential in durcabtagene autoleucel products. Maintenance of Tscm in manufactured products contributes to robust CAR-T expansion and long-term persistence of CAR-T cells with a highly diverse TCR repertoire after infusion.
Traditional CAR T-cell manufacturing requires extended ex vivo cell culture, reducing naive and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which expresses the same validated CAR as tisagenlecleucel, can be manufactured in <2 days while retaining T-cell stemness and enhancing clinical activity at a 25-fold lower dose.
top 20 pharma companies by 2023 revenue |
Another strange day. 3,707 shares traded as I type, but I'd bet a pound of Dom's money that its somewhere near to 200k in total at the end of the day.
Hopefully a fortnight today will be a much more interesting day. |
I guess at some point (if CAR-T is to become mainstream and not the treatment of last resort - or next to last resort) then it either has to move to an outpatient setting or they need to build more facilities.
Maybe you remember this, but we are involved with T-Charge (Novartis) which is a CAR-T drug in current trials, which is grown on inside the patient (not a bioreactor).
My understanding / recollection from the time is that instead of the modified T-Cells being grown on in a warm bioreactor until there are a huge number to purify and infuse back into the patient as one massive assault, they infuse a much smaller number directly into the patient and do it sooner than would normally be possible.
The cells then multiply on inside the patient whilst looking for the target they have been programmed (with LentiVector) to kill.
If this works out in trials then not only is the patient less poorly at infusion time because of having to wait less time for the product, but the common "storm" reaction when the immune system is suddenly "switched on" (by T-Cells which can "see" the enemy) is much milder because the patient is given many less modified T-Cells.
Might not be 100% there, but that's the general gist of it and Novartis see T-Charge as replacing Kymriah with a simpler / quicker process which is easier on the patients - so I would assume that means outpatient. A while to wait yet for T-Charge though. |
Interesting and comprehensive article regarding a shift in thinking regarding in- outpatient Car-T planned treatments versus inpatient treatments-should improve no. of future treatments offered significantly and the healthcare provider bottom line -which in turn will offer more treatments and so on |
https://chi.scholasticahq.com/article/115793 |
Another great find Phil.
Aside from the interesting content there, I'd suggest that video also tells us that we are still on excellent terms with both Miles and Peel Hunt (the previous house broker and analyst of course) which is good to see.
I wonder if this was instigated by a request from PH or if there has been some kind of charm offensive going on with all the covering brokers? I'm thinking the latter but I guess we will never know the answer to that one.
I think another very positive sign is the link with the US team visiting - everything everywhere as Frank (in his Cadbury's milk tray man outfit) might say. |
Inside Windrush court:
Other links of interest |
Make of it what you will but you can currently buy 25000 shares at 208.5 on quote and deal.That’s quite chunky for OXB.There’s stock about. |
It's far from clear Dom (imho) and if that regular seller is still with us, then did they really just have a day off yesterday?
Just to give the stuck record another airing, I think the 2023 results presentation (which, the way these things work, is really the first proper 2024 presentation) is the elephant in the room here.
We said that would be on us before we knew it and of course it's a fortnight on Monday now.
Put in other words, only 10 working days for OXB to announce something now if there is anything in my theory that they gave an unusually long notice of the results this year because they wanted to announce something before the presentation...
That aside, we have the obvious mismatch of what OXB have said they are going to present and what the covering analysts (and the market) think reality is.
Where does that leave us? Nobody knows yet.
6 weeks ago Stuart said that 2024 revenue will be £126m to £134m.
Perhaps more pertinent is that 2025 is indicated as better than £170m to £181m, which would be our record best ever year and unlike during covid we would not have 87% of our work in one customer contract.
What will happen? Who knows, but a fortnight will very quickly pass and then we have this quite odd situation where the company has stopped burning money on operations and is already looking at projections of next year's record earnings, whilst trading on a little more than a tenth of our 3 year high share price. |
We still have a seller then! |
Back down for now.
Any boost if we get one will probably be around mid-afternoon. |
Another building block from NICE. All helps and the more Kymriah is used the more acceptable it will become and the more revenue for OXB. |
As I recall (so there's your warning) it was approved back in 2018, but only in very specific circumstances. What PB has found there is that they now plan to treat with it routinely - as per this same story from a different site:-
As for was this the news that I thought OXB might be trying to time to get in before the results? No. |
Harry, is that new news in terms of positive for the share price and not specifically expected right now i.e. might help the share price a little given how stuck we have been. Not seeing any numbers makes it hard to guage.. |
Winner of today's observer badge award for spotting that one PB.
It all helps in this rolling snowball known as OXB's revenue.
Obviously more vector to be made, but as I'm sure you remember we have a royalty on sales for Kymriah, so every sale notches that up.
JD at the time said words to the effect that it's a very small percentage, but that a very small percentage of a very big number is still a lot of money. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
